CHARLOTTETOWN, Prince Edward Island--(BUSINESS WIRE)--Neurodyn Life Sciences Inc. announced completion of its first-in-human clinical study, demonstrating Memogain’s potential benefits over existing Alzheimer’s drugs;
* increased safety in the absence of significant side effects,
* more potent cognitive enhancement.
The Phase IA clinical trial addressed safety, tolerability, and pharmacokinetics of intranasally delivered Memogain® in healthy young and elderly subjects, compared to the daily recommended doses of the current Alzheimer’s drugs: galantamine (16 mg) and donepezil (10 mg). Study participants were additionally tested for improved cognition.
Help employers find you! Check out all the jobs and post your resume.
